Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 4, 2026
- Charles River Laboratories reported third-quarter revenue of $982.7 million, 4.7% organic growth, and non-GAAP diluted EPS of $3.09. It raised 2026 organic revenue guidance to at least +1.5% and non-GAAP EPS guidance to $11.35 – $11.55.
- 10-Q report · filed Nov 4, 2026
- Charles River Laboratories International, Inc. reported revenue of $982.7 million, down 2.2%, and operating income of $202.6 million. Net income attributable to common shareholders reached $333.1 million, helped by a $201 million tax benefit.
The audio replay and transcript follow the call.